Harvard Bioscience, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless stated otherwise. Harvard Bioscience develops, manufactures, and sells technologies, products, and services for life-science research and pharmaceutical and therapy development.
Financial performance
- Revenue: $24.5 million, down 18.2% from $30.0 million. Management attributed the decline primarily to softer worldwide demand, especially in Asia-Pacific, against a strong prior-year quarter. China revenue fell to $4.4 million from $6.5 million.
- Profitability: Gross profit was $14.8 million, down 19.5%; gross margin decreased to 60.3% from 61.2%, mainly due to under-absorption of manufacturing overhead. Operating loss was $2.3 million versus operating income of $1.7 million. Net loss was $4.7 million, or $0.11 per diluted share, versus net income of $0.6 million, or $0.01 per diluted share.
- Expenses and unusual items: Operating expenses included $1.0 million of other operating costs: a $0.5 million fee related to employee retention credit claims and a $0.5 million accrual for an unclaimed-property audit. A $1.3 million loss on HRGN equity securities included $0.3 million realized and $1.0 million unrealized loss.
- Cash flow: Operating cash flow was $1.4 million versus $1.8 million. Investing used $0.2 million; financing used $1.1 million. Cash decreased $0.03 million to $4.3 million. Operating cash flow included receipt of $3.2 million in employee retention credits, which remains recorded as a liability pending determination that it qualifies for recognition.
- Liquidity and debt: Current assets were $48.1 million and current liabilities $25.7 million (working capital $22.5 million). Gross borrowings were $36.1 million, compared with $37.1 million at year-end; cash was $4.3 million. The $25.0 million revolving facility had $4.4 million of available capacity, subject to leverage limitations. The weighted-average borrowing rate, net of swaps, was 7.4%. Debt matures December 22, 2025; the company was in compliance with amended covenants at quarter-end.
- Other metrics: Total assets were $133.2 million and stockholders’ equity $68.8 million at March 31, 2024. Interest expense declined to $0.8 million from $1.0 million.
Material changes and management commentary
Revenue contraction drove lower gross profit and a shift from operating income to operating loss. Gross margin contracted 0.9 percentage points. Sales and marketing, general and administrative, and research and development expenses were broadly stable in dollars, while their shares of revenue increased. Management cited higher costs of capital and reduced post-pandemic spending by biotech and pharmaceutical customers, weaker China and Asia-Pacific markets, and delays in government funding. The company stated that prolonged or worsening conditions could materially affect results and cash flow.
Management expects available cash, operating cash generation, and debt capacity to fund operations and capital expenditures for at least the next 12 months, based on current plans. The filing provides no formal revenue or earnings guidance. A March 2024 credit agreement amendment adjusted covenant EBITDA for specified audit-related charges and employee-retention-credit fees. The company also held an interest-rate swap with a $25.9 million notional amount, effectively fixing the SOFR component at 4.75% through December 2025, excluding the credit margin.
Risks, contingencies, and other disclosures
- The employee retention credit refund is subject to accounting recognition uncertainty; the company recorded the $3.2 million receipt in other current liabilities. It paid a $0.5 million related service fee.
- An ongoing unclaimed-property audit resulted in a $0.5 million accrued loss; additional assessments could include interest and penalties.
- The HRGN investment had a reported fair value of $1.7 million at quarter-end. The filing warns that its value could fluctuate substantially or become worthless because of limited trading liquidity and the issuer’s financial condition.
- The company disclosed ordinary-course legal matters but said it had not accrued losses because unfavorable outcomes were not considered probable and reasonably estimable. It noted an adverse resolution could be material.
- Management reported effective disclosure controls and no material changes to internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether demand, particularly in China and Asia-Pacific, stabilizes and whether revenue and gross margins recover.
- The status and ultimate recognition of the $3.2 million employee retention credit, including any repayment exposure.
- Developments in the unclaimed-property audit and whether liabilities exceed the $0.5 million accrual.
- Compliance with credit-facility covenants, revolver availability, and refinancing or repayment plans ahead of the December 2025 maturity.
- Further changes in the value or liquidity of HRGN shares and the resulting earnings impact.